Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single-arm, open-label trial study of THX-RS01 in treating Tourette syndrome

Next Previous
X
Search
Trial Profile

A single-arm, open-label trial study of THX-RS01 in treating Tourette syndrome

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Feb 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dronabinol/palmitoylethanolamide (Primary)
  • Indications Gilles de la Tourette's syndrome
  • Focus Proof of concept; Therapeutic Use

    • Most Recent Events

    • 20 Aug 2018 According to a Therapix Biosciences media release, the results were presented at the annual meeting of the European Society for the Study of Tourette Syndrome 2018.
    • 11 Jun 2018 According to Therapix Biosciences Ltd. media release, the results from this study will be presented at the 11th European Society for the Study of Tourette Syndrome (ESSTS) conference in June.
    • 31 May 2018 Status changed from active, no longer recruiting to completed, according to a herapix Biosciences media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top